Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection ...

For each region and country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and the breakdown of each national market by ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy for adult patients with unresectable or metastatic hormone receptor ...

The Munich-based company has confirmed that its prospective, randomised, open-label trial of ITM-11 met its primary endpoint demonstrating a statistically significant benefit in progression-free ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Other Trump executive orders included repealing a 2022 Biden executive order to test Medicaid models to lower the price of drugs and orders related to access to Covid-19 vaccines and treatments.

In 2020, the U.S. Centers for Disease Control and Prevention confirmed the United States' first known case of novel coronavirus -- what would later come to be known as COVID-19. In 2021 ...

However, the asset faced a series of setbacks in 2024. The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s Dato-DXd, to be known as Datroway, for patients with certain advanced breast ...

Datroway will cost nearly $4,900 per vial, Reuters reported. The treatment will hit U.S. shelves in approximately two weeks, according to Daiichi Sankyo’s announcement of the approval. In a note to ...